ImpediMed

ImpediMed Operating Expenses

The Total Operating Expenses of ImpediMed (IPD.AX) as of Nov 3, 2026 is 22.74 M AUD. In the previous year, Total Operating Expenses was 21.66 M AUD — a change of 4.98% (higher).

Operating Expenses

22.74 MAUD

YoY

4.98%

Last updated:

Total Operating Expenses of ImpediMed is 2026 22.74 M AUD. Total Operating Expenses of ImpediMed was 2025 21.66 M AUD. It decreases by 4.98% higher compared to the previous year.

The ImpediMed Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2019
24.01 M AUD
Jan 1, 2020
23.40 M AUD
Jan 1, 2021
23.98 M AUD
Jan 1, 2022
20.24 M AUD
Jan 1, 2023
20.10 M AUD
Jan 1, 2024
22.32 M AUD
Jan 1, 2025
21.66 M AUD
Jan 1, 2026
22.74 M AUD
The ImpediMed Operating Expenses history
YEAROperating ExpensesYoY
22.74 MAUD+4.98%
21.66 MAUD-2.93%
22.32 MAUD+11.00%
20.10 MAUD-0.67%
20.24 MAUD-15.60%
23.98 MAUD+2.49%
23.40 MAUD-2.53%
24.01 MAUD+141.10%
9.96 MAUD-63.83%
27.53 MAUD+19.79%
22.98 MAUD+71.04%
13.44 MAUD+290.89%
3.44 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Total Operating Expenses of ImpediMed is 22.74 M AUD in 2026.

Total Operating Expenses of ImpediMed changed from 21.66 M AUD to 22.74 M AUD, representing a 4.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ImpediMed

All Key Metrics — ImpediMed